BigHat Biosciences is a biotechnology company developing safer, more effective antibody therapies for patients using machine learning and synthetic biology.
BigHat’s mission is to improve human health by making it far easier to design advanced, next-generation antibody therapeutics.
BigHat Biosciences was founded in 2019 by Mark DePristo and Peyton Greenside. The company is headquartered in San Carlos, California.
BigHat’s AI-enabled antibody design platform, Milliner, offers the essential technologies to quickly and reliably create these breakthrough therapies. BigHat is using MillinerTM to design safer, more effective antibody therapies to treat some of the world’s most intractable conditions, from chronic illnesses to life-threatening diseases.
BigHat’s machine learning models design hundreds of variants that are built and tested in their lab using the latest synthetic biology technologies in each cycle. These measurements include biophysical properties and impact on disease activity for every variant using cell-based or other functional assays that replicate in vivo disease processes.
BigHat has active therapeutic programs spanning multiple domains of human health, including inflammation, oncology, and infectious diseases in preclinical studies.
BigHat is backed by 8VC, Andreessen Horowitz, Section 32, Amgen Ventures, Bristol Myers Squibb, AME Cloud Ventures, Innovation Endeavors, Quadrille Capital, Gaingels, GRIDS Capital, and others. The company raised $75M in Series B round on Jul 20, 2022. This brings BigHat's total funding to $99.3M to date.